Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. David Braxton, Chief of Service for Molecular Pathology at Hoag Hospital in Newport Beach, California. Explore Dr. Braxton's remarkable career as a molecular pathologist and delve into the pivotal role molecular pathologists play in precision oncology, while examining the progressive integration of artificial intelligence within molecular pathology.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. David Braxton: Molecular Pathology and Precision Medicine

Join Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, and Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute, as they delve into the depths of radiation therapy in cancer care. Together they unravel the intricacies of this vital treatment option, covering its mechanisms, innovations, and the pivotal role it plays in the journey towards effective oncological treatment for patients.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Salma Jabbour: Radiation Therapy Simplified

Join Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance, in a captivating podcast conversation with special guest Dr. Emil Lou, Associate Professor of Medicine at the University of Minnesota. Delve into the intricate connections between pathogens and cancer, exploring both research breakthroughs and the clinical implications. Gain valuable insights into the current landscape and discover what the future holds for this dynamic intersection of science and medicine.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Emil Lou: Pathogens and Cancer Associations

Synopsis: 
Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the differences in responsibility between being a CEO and a board member. He also shares what it takes to have a productive board for a biotech company. He discusses recruiting at both the team level and the board level and the qualities that he looks for in a candidate. He shares where he thinks cancer drug development is headed, where it needs to head and where he thinks there’s unmet need. Finally, he talks about the work they’re pursuing at Kura and where they are from a development perspective.

Biography:
Troy E. Wilson, Ph.D., J.D., is one of Kura’s Co-founders and has served as our President and Chief Executive Officer and as the Chairman of our Board of Directors since our inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, from November 2012 to February 2019.

Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since October 2013, Chairman and a member of the Board of Directors of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, since February 2019 and November 2012, respectively, Executive Chairman and a member of the Board of Directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the Board of Managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.

The promise of precision oncology, Troy Wilson, President & CEO, Kura Oncology

Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. Ari VanderWalde, Global Head of Clinical Trials at Caris Life Sciences. Join them as they delve into the world of clinical trials, exploring the intricacies of clinical research, providing valuable insights into Caris' contributions, and the accessibility of these transformative opportunities.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Ari VanderWalde - Clinical Trials at Caris Life Sciences: The Path Forward

Uncover the path to equitable clinical trials in the latest Caris Molecular Minute podcast with host Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance and his guest, Dr. Ishwaria Subbiah, Executive Director at Sarah Cannon Research Institute. Together, they explore ways to enhance patient access and enrollment, mitigate disparities, and foster equality in clinical trials. Don't miss this thought-provoking conversation aimed at reshaping the narrative for a more inclusive and impactful future in cancer care and research.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Ishwaria Subbiah: Equity in Clinical Trials

Join host Dr. Chadi Nabhan and special guest Dr. Rachna Schroff, Chief, Division of Hematology/Oncology and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona as they take a deep dive into the latest highlights from this year’s ASCO-GI meeting. Explore novel oncology research, groundbreaking trials, and the transformative role molecular profiling and liquid biopsies are playing in revitalizing the field of gastrointestinal cancer. Don’t miss these essential highlights from this year’s meeting.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Rachna Schroff: Highlights from 2024 ASCO-GI

Welcome to the Business Talk Podcast!

We are delighted to welcome the highly esteemed Dr. Matthew Kurian to join us today.

In this episode, Dr. Kurian will explore his expertise topic, "Transforming Cancer Care: How AI, Precision Medicine, and Innovative Therapies Are Shaping the Future of Oncology."
The landscape of cancer care is undergoing a revolutionary transformation, driven by advancements in artificial intelligence (AI), precision medicine, and innovative therapies. AI is enabling more accurate diagnosis, predictive analytics, and personalized treatment plans, allowing oncologists to detect cancer earlier and tailor interventions to individual patients. Precision medicine leverages genetic profiling to target therapies specific to a patient’s unique cancer mutations, increasing treatment efficacy and minimizing side effects. Breakthrough therapies, such as immunotherapy, radioligand treatments, and gene therapies, are providing new hope for patients with previously untreatable cancers.

Together, these innovations are reshaping oncology, offering more effective and personalized treatments, improving patient outcomes, and pushing cancer care into a new era of medical advancement. The future of oncology lies in integrating these technologies, making cancer treatment more adaptive, targeted, and accessible to all.

About the Guest:

Dr. Matthew Kurian is a dedicated hematology/oncology physician at St. Elizabeth Healthcare and an assistant professor of medicine at the University of Kentucky College of Medicine. Specializing in breast and genitourinary cancers, Dr. Kurian has a wealth of experience with radioligand therapies, particularly Lu-177. He completed his oncology fellowship at the NCI-designated University Hospitals/Case Comprehensive Cancer Center, where he served as the Chief Fellow of the Hematology/Oncology Fellowship Program for 2022-2023 and has numerous peer-reviewed publications to his name.

Beyond clinical practice, Dr. Kurian is passionate about narrative medicine, medical education, and improving clinical trial access in community settings. As the Cancer Center Physician Liaison at St. Elizabeth and a member of the Executive Committee of KYSCO (the state affiliate of ASCO), he aims to enhance the availability of GU and breast cancer trials in his region. He previously taught at Case Western Reserve University School of Medicine, earning the 2023 Fellow Teacher of the Year Award and being inducted into the Academy of Scholars.

This podcast is brought to you by Global Management Consultancy. For more information, please visit www.globalmanagementconsultancy.com.

Disclaimer:

A. The background music used in this video is the property of its respective developer and is protected by Copyright. Although it is a free version, Business Talk, Global Management Consultancy and Deepak Bhatt do not hold the rights to this music.

B. Dr. Matthew Kurian has granted permission to share insights from the topic, “Transforming Cancer Care: How AI, Precision Medicine, and Innovative Therapies Are Shaping the Future of Oncology” on Business Talk Podcast Channel. The uploaded video contains copyrighted material; therefore, any modifications to graphics, music, or the presence of the author or host are strictly prohibited.

Innovative Cancer Therapies: Dr. Matthew Kurian's Insights on AI and Precision Oncology

BUFFALO, NY - March 18, 2025 – A new precision oncology paper was #published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients."

Led by Oncotarget Editor-in-Chief Dr. Wafik S. El-Deiry and a global team of researchers, this special publication highlights the groundbreaking work of the Worldwide Innovative Network (WIN) Consortium, a global collaboration dedicated to transforming cancer care through personalized medicine. By leveraging artificial intelligence (AI), molecular profiling, and innovative clinical trials, WIN is helping clinicians tailor treatments to each patient’s unique cancer profile—moving beyond the traditional one-size-fits-all approach.

The WIN Consortium is a fast-moving, non-profit organization bringing together nearly 40 academic, industry, and research institutions, along with patient advocacy groups, across 18 countries and five continents. Founded in 2010 in France by Dr. John Mendelsohn (MD Anderson Cancer Center) and Dr. Thomas Tursz (Gustave Roussy), WIN has been led by different renowned experts. Currently under Dr. El-Deiry’s leadership, WIN continues to break barriers in cancer research, ensuring cutting-edge treatments reach patients worldwide.

“The WIN global consortium is ready to take up the challenge by bringing the best possible Precision Oncology trial to patients.”

One of WIN’s most significant contributions is the development of N-of-1 clinical trials, a revolutionary approach that personalizes cancer treatment based on a patient’s specific tumor characteristics. Unlike traditional trials that test drugs on large groups, N-of-1 trials focus on finding the best therapy for an individual patient using AI-driven algorithms, genomic analysis, and real-world data. WIN’s WINTHER trial was one of the first to use both DNA and RNA analysis to match patients with the most effective therapies, while the WINGPO trial builds on this approach by integrating AI and liquid biopsies to refine treatment selection. These innovations are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.

While advancing research, the WIN Consortium is also addressing major challenges in precision oncology, including drug accessibility, regulatory barriers, and disparities in global healthcare. By working closely with governments, pharmaceutical companies, and advocacy organizations, WIN is aiming to ensure that life-saving treatments are accessible to all patients, regardless of location or financial status.

WIN’s mission is clear: to accelerate the future of precision oncology by delivering the latest scientific advancements into real-world cancer care. As the field continues to evolve, WIN remains at the forefront, developing next-generation trials and leveraging AI-driven insights to improve patient outcomes. Through global collaboration and groundbreaking research, the WIN Consortium is shaping a future where every cancer patient receives the most effective, personalized treatment possible.

DOI - https://doi.org/10.18632/oncotarget.28703

Correspondence to - Wafik S. El-Deiry - wafik@brown.edu

Video short - https://www.youtube.com/watch?v=XAdYfFoMvUM

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com.

MEDIA@IMPACTJOURNALS.COM

Oncotarget

WIN Consortium Leading the Future of Precision Cancer Medicine

BUFFALO, NY – August 15, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 13, 2025, titled “Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay.”

In this study, first authors Valeriy Domenyuk and Kasey Benson, along with corresponding author David Spetzler from Caris Life Sciences in Irving, Texas, introduce MI Cancer Seek, an FDA-approved test designed to deliver comprehensive tumor profiling. MI Cancer Seek demonstrated strong concordance with other FDA-approved companion diagnostics and serves as a powerful tool to guide treatment decisions in both adult and pediatric cancer patients.

Cancer remains one of the most complex and diverse diseases to treat. With many targeted therapies currently FDA-approved, selecting the right one for a specific patient requires detailed genetic insights. MI Cancer Seek addresses this need by analyzing both DNA and RNA from a single tumor sample. The tool identifies key biomarkers linked to FDA-approved treatments for several major cancers, including breast, lung, colon, melanoma, and endometrial cancers.

One of the most significant strengths of MI Cancer Seek is its ability to deliver accurate and reliable results from minimal tissue input (50 ng). Even when analyzing formalin-fixed paraffin-embedded samples, which are widely used but often degraded, the test maintained high levels of accuracy. It successfully detected important genetic alterations such as PIK3CA, EGFR, BRAF, and KRAS/NRAS mutations and measured tumor mutational burden (TMB) and microsatellite instability (MSI), both of which are key indicators for immunotherapy response.

In clinical comparisons, the test achieved over 97% agreement with other FDA-approved diagnostic tools, confirming its reliability in detecting critical biomarkers. Notably, it showed near-perfect accuracy in identifying MSI status in colorectal and endometrial cancers. The researchers also demonstrated that the test maintains precision across different lab conditions and varying DNA input levels, confirming its robustness for routine clinical use.

Beyond its role as a companion diagnostic, MI Cancer Seek incorporates additional features developed under its predecessor, MI Tumor Seek Hybrid. These include detection of homologous recombination deficiency, structural variants, and cancer-related viruses. It also includes advanced tools such as the Genomic Probability Score for identifying the tissue of origin in cancers of unknown primary, as well as a gene signature to guide first-line chemotherapy in colorectal cancer.

“One limitation to be considered is the low PPA for ERBB2 CNA detection.”

By offering deeper genetic insights from a single, small sample, MI Cancer Seek has the potential to streamline diagnostics, reduce testing costs, and connect patients to effective therapies more quickly. As precision medicine continues to expand, this assay stands out as a comprehensive and efficient solution for meeting the evolving needs of modern oncology.

DOI - https://doi.org/10.18632/oncotarget.28761

Correspondence to - David Spetzler - dspetzler@carisls.com

Video short - https://www.youtube.com/watch?v=D4hd2FxCYY8

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

FDA-Approved MI Cancer Seek Test Enhances Tumor Profiling for Precision Oncology

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Welcome to Business Talk, your go-to podcast for the latest trends, insights, and thought-provoking discussions in the business world. Whether you're a business professional, entrepreneur, researcher, or academic, our episodes will challenge you to rethink conventional wisdom and inspire actionable ideas.

Brought to you by Global Management Consultancy, we are committed to driving innovation and excellence in the business community. All content Copyrighted 2024 by Global Management Consultancy.

For more information about our past and upcoming podcasts, please click here:https://www.deepakbbhatt.com/businesstalk

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

New tracks tagged #precisiononcology